Raptor Pharmaceutical Corp., of Novato, Calif., reported global net product revenue of $32 million for the second quarter, up 37.3 percent over the same period in 2015, which Raptor attributed to further market penetration in the U.S. and Europe for Procysbi (cysteamine bitartrate delayed-release), approved for orphan disease nephropathic cystinosis. GAAP net loss was $14 million, or 16 cents per share, while non-GAAP net loss was $11.3 million, or 13 cents per share. The firm ended the quarter with cash and equivalents of $124.2 million. Shares of Raptor (NASDAQ:RPTP) closed Friday at $6.89, up 37 cents.